BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38319510)

  • 1. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.
    Nomura K; Aokage K; Kaminuma Y; Nakai T; Wakabayashi M; Ikeno T; Koike Y; Taki T; Miyoshi T; Tane K; Samejima J; Ishii G; Tsuboi M
    Int J Clin Oncol; 2024 Mar; 29(3):248-257. PubMed ID: 38319510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
    Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
    Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
    Ito H; Date H; Shintani Y; Miyaoka E; Nakanishi R; Kadokura M; Endo S; Chida M; Yoshino I; Suzuki H;
    BMC Cancer; 2022 Aug; 22(1):875. PubMed ID: 35948946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma.
    Hong TH; Hwang S; Choi YL; Lee G; Park S; Ahn MJ; Lee Y; Jeon YJ; Lee J; Shin S; Park SY; Cho JH; Choi YS; Kim J; Shim YM; Cho J; Kim HK
    Histopathology; 2023 Aug; 83(2):168-177. PubMed ID: 36849852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
    Lee JS; Kim EK; Kim KA; Shim HS
    Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.
    Liu X; Li X; Zhang C; Jin J; Wang Z; Xiao R; Sun K; Wang J; Zhong W; Yang F
    Lung Cancer; 2022 May; 167():78-86. PubMed ID: 35427848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
    Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
    BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.
    Kamigaichi A; Mimae T; Tsubokawa N; Miyata Y; Adachi H; Shimada Y; Ito H; Ikeda N; Okada M
    Ann Thorac Surg; 2024 Apr; 117(4):743-751. PubMed ID: 36739066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
    Xu L; Guo R
    Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea.
    Woo W; Yang YH; Cha YJ; Moon DH; Shim HS; Cho A; Kim BJ; Kim HE; Park BJ; Lee JG; Kim DJ; Paik HC; Lee S; Lee CY
    Thorac Cancer; 2022 Dec; 13(23):3310-3321. PubMed ID: 36345148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade tumor classified by new system is a prognostic predictor in resected lung adenocarcinoma.
    Yoshida C; Yokomise H; Ibuki E; Go T; Haba R; Kadota K
    Gen Thorac Cardiovasc Surg; 2022 May; 70(5):455-462. PubMed ID: 35050467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological high malignant grade is higher risk of recurrence in pN0M0 invasive lung adenocarcinoma, even with small invasive size.
    Ito M; Miyata Y; Kushitani K; Kagimoto A; Ueda D; Tsutani Y; Takeshima Y; Okada M
    Thorac Cancer; 2021 Dec; 12(23):3141-3149. PubMed ID: 34643053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
    Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
    Lee KH; Chung JH; Cho S; Lee JS; Kim H
    Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
    Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma.
    Woo W; Cha YJ; Kim BJ; Moon DH; Lee S
    Clin Lung Cancer; 2022 Nov; 23(7):e435-e442. PubMed ID: 35945128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.